v3.26.1
Segment Reporting (Tables)
9 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Information by Segments

The summary of key information by segments for the nine months ended March 31, 2026 was as follows: 

 

   Pharmaceutical
distribution
(China)
   Holding  

Total for the
nine months
ended
March 31,

2026

 
Revenue from external customers  $5,108,387   $
-
   $5,108,387 
Cost of revenue  $2,333,460   $
-
   $2,333,460 
Gross profit  $2,774,927   $
-
   $2,774,927 
Selling expense  $1,785,669   $19,128   $1,804,797 
General and administrative expense  $481,389   $3,401,777   $3,883,166 
Depreciation & amortization  $36,556   $65,475   $102,031 
Income tax expense  $126,661   $(16,029)  $110,632 
Long-lived assets  $400,377   $334,612   $734,989 
Segment assets  $3,774,605   $14,006,046   $17,780,651 
Segment profit (loss)  $246,745   $(3,699,622)  $(3,452,877)

 

The summary of key information by segments for the nine months ended March 31, 2025 was as follows: 

 

   Pharmaceutical
distribution
(China)
   Holdings  

Total for the
nine months
ended
March 31,

2025

 
Revenue from external customers  $715,362   $
–
   $715,362 
Cost of revenue  $240,966   $
–
   $240,966 
Gross profit  $474,396   $
–
   $474,396 
Depreciation & amortization  $4,262   $32,946   $37,208 
General and administrative expense  $246,685   $1,556,794   $1,803,479 
Income tax provision  $26,608   $(8,014)  $18,594 
Capital expenditure  $155,991   $
–
   $155,991 
Long-lived assets  $348,179   $493,157   $841,336 
Segment assets  $1,090,942   $2,224,881   $3,315,823 
Segment profit (loss)  $70,616   $(1,600,218)  $(1,529,602)